Revive Therapeutics extends private placement offering deadline

Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced an extension of its private placement offering of up to 30,952,381 units at $0.021 per unit for gross proceeds of up to $650,000.

The Toronto-based life sciences company closed a first tranche in August 2025, issuing 2,900,000 units for gross proceeds of $60,900. The company may close an additional $589,000 worth of units under the extended offering.

Each unit consists of one common share and one warrant. The warrants allow holders to purchase one common share at $0.05 for 36 months following closing. The unit price was based on the 20-day volume-weighted average price of shares traded on the Canadian Securities Exchange when the company obtained price protection.

Revive stated the proceeds will fund working capital and payment of trade payables. The private placement may close in multiple tranches, subject to customary closing conditions. All securities will have a four-month-and-one-day hold period from issuance.

The company develops therapeutics for medical needs and focuses on drug development programs targeting FDA regulatory incentives including Emergency Use Authorization and Orphan Drug designations. Current programs include Bucillamine for infectious diseases, psilocybin, and molecular hydrogen therapeutics.

You May Also Be Interested In